the amino acid sequence of SEQ ID NO: 6, and CDRs (*i.e.,* heavy chain CDR1, CDR2, and CDR3) described in the amino acid sequence of SEQ ID NO: 1.

In a further embodiment, the methods and compositions of the invention feature an auristatin which is either monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF).

In one embodiment, the MMAE is conjugated to the antibody via a valine-citrulline (vc) linker (vc-MMAE). In another embodiment, the MMAF is conjugated to the antibody via a maleimidocaproyl linker (mc-MMAF).

In one embodiment, the composition of the invention is a pharmaceutical composition.

In one embodiment, there is provided a pharmaceutical composition comprising the composition as described herein and a pharmaceutically acceptable carrier.

Also included in the invention are methods of treating cancer in a subject comprising administering a composition described herein to the subject such that cancer is treated. In one embodiment, the cancer is selected from the group consisting of squamous tumors (including, squamous tumors of the lung, head and neck, cervical, etc.), glioblastoma, glioma, non-small cell lung cancer, lung cancer, colon cancer, head and neck cancer, breast cancer, squamous cell tumors, anal cancer, skin cancer, and vulvar cancer.

In one embodiment, the compositions of the invention are used to treat glioblastoma multiforme.

In one embodiment, the compositions of the invention are used to treat a solid tumor having overexpression of EGFR. In one embodiment, the compositions of the invention are used to treat a subject having an advanced solid tumor likely to overexpress EGFR.

In one embodiment, the compositions of the invention are administered intravenously.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides an overview of the processes described in the examples, including reduction of Antibody 1, conjugation of Antibody 1 to vcMMAE, and purification of the ADC using batch purification with HIC resin.

Figure 2 graphically depicts HIC HPLC analysis of an Antibody 1 ADC solution before and after HIC resin batch purification.

Figure 3 provides an overview of the process described in Example 6 for the purification of ADC mixtures with average DARs of 2.7, 4, and 5.5.

What is claimed is:

1. A composition comprising ADCs, wherein 70% of ADCs present have a drug loaded species of 4 or less, and wherein the ADC comprises an anti-EGFR antibody and an auristatin.

2. The composition of claim 1, wherein 75% of ADCs present have a drug loaded species of 4 or less.

3. The composition of claim 1, wherein 80% of ADCs present have a drug loaded species of 4 or less.

4. The composition of claim 1, wherein 85% of ADCs present have a drug loaded species of 4 or less.

5. The composition of claim 1, wherein 90% of ADCs present have a drug loaded species of 4 or less.

6. The composition of claim 1, wherein 95% of ADCs present have a drug loaded species of 4 or less.

7. The composition of any one of claims 1-6, wherein the anti-EGFR antibody comprises a light chain variable region comprising a Complementarity Determining Region 1 (CDR1), CDR2, and CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, respectively, and comprises a heavy chain variable region comprising a CDR1, CDR2, and CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.

8. The composition of any one of claims 1-6, wherein the anti-EGFR antibody comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID

NO: 6 and a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1.

9. The composition of any one of claims 1-8, wherein the auristatin is either monomethylauristatin E (MMAE) or monomethylauristatin F (MMAF).

10. The composition of claim 9, wherein the MMAE is conjugated to the antibody via a valine-citrulline (vc) linker.

11. The composition of claim 9, wherein the MMAF is conjugated to the antibody via a malemidocaproyl (mc) linker.

12. A pharmaceutical composition comprising the composition of any one of claims 1-11 and a pharmaceutically acceptable carrier.